Overview

Study Examining PrEP-001 in Subjects With Asthma

Status:
Completed

Trial end date:
2016-09-01

Target enrollment:

Participant gender:

Summary

Phase 2 study, to examine the prophylactic efficacy, safety and tolerability of PrEP-001 in asthmatics who have been infected with the human rhinovirus (HRV16) after receiving two doses of the study drug/placebo.

Phase:

Phase 2

Details

Lead Sponsor:

Hvivo

Collaborator:

Prep Biopharm Limited